Poop pills aim to wipe out superbugs in the gut
NCT ID NCT05981430
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether swallowing capsules containing healthy donor stool can clear carbapenem-resistant Enterobacteriaceae (CRE) from the gut of hospitalized patients. CRE are superbugs that resist many antibiotics and can cause serious infections. The trial will compare the capsules to a placebo in 80 adults at a Hong Kong hospital, measuring how many patients clear the bacteria after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fecal microbiota transplant (FMT) capsules
- What this could lead to
- If it works, this could offer a way to remove dangerous drug-resistant bacteria from the gut without antibiotics, reducing infection risk.
- What could go wrong
- This is a small, early-stage trial with only 80 participants. The treatment may not clear the bacteria, and there are risks like infection or side effects from the transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARBAPENEM-RESISTANT ENTEROBACTERIACEAE INFECTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a fecal transplant stop dangerous brain fog after liver surgery?
- Superbug sleuths decode the DNA of drug-resistant e. coli to stop its spread
- Could poop transplants save sepsis patients?
- Poop pills plus chemo: new hope for stubborn colon cancer?
- Poop pills for newborns: could a fecal transplant prevent obesity?
- What puts kids in the ICU at risk for a superbug infection?